SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Chiron
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: vinod Khurana who wrote (1)5/17/1996 1:40:00 PM
From: vinod Khurana   of 23
 
Nabi Inc. Starts Production Of CMV Disease-Preventing Drug

BOCA RATON, Fla. (Dow Jones)--Nabi Inc. (NABI) started work on the production of CMV NeutraGAM, an antibody-based therapeutic drug that could possibly prevent CMV disease in patients who receive solid organ transplants.

In a press release, the company said the product marks the first to result from its agreement with Chiron Corp. (CHIR), Emeryville, Calif., under which Nabi has exclusive rights to use several of
Chiron's vaccines.

In this case, Nabi will use Chiron's Cytomegalovirus vaccine and inject it into healthy donors which should produce antibodies. Nabi will then produce NeutraGAM with the anitbodies and use it in clinical trials later this year to see if it prevents CMV disease in donor receipients.

As part of the agreement, both Chiron and Nabi will share the profits resulting from any sales of the product.

Chiron Corp. and Nabi Inc. are biotechnology companies.

V.K
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News